The EC has approved BeiGene’s PD-1 inhibitor Tevimbra in combination with chemotherapy to treat ESCC and G/GEJ adenocarcinoma ...
In recent years, the evolution of biologic therapies for severe asthma has paralleled advancements in other chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback